We would like to notify that for the month of March, 2012 Sopharma AD realized decrease of sales revenues of 14% compared with the same month of the previous year, including 10% decrease of domestic sales and 16% decrease of export sales.

During the last two months we managed to compensate the decrease from January, caused by force major conditions and we finish the first quarter of 2012 with 3% decrease of sales revenues compared with the same quarter of 2011, including 18% decrease of domestic sales and 3% increase of export sales.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 5 April 2012 up to and including 11 April 2012 the Company bought 500900 own shares representing 0.379% of the share capital of the Company, to the total value of BGN 1137354 on the Bulgarian Stock Exchange. The average price per share was BGN 2.27.

The shares have been bought on the basis of the general meeting resolution of 23.06.2010.

Sopharma AD (the “Company”) notifies that for January 2014 the Company recorded an increase of sales revenues of 6% compared to the same period of 2013, including 2% increase of domestic sales and 9% increase of export sales.

Sopharma AD (the “Company”) announces that on 18 June 2013 the Company bought 4 039 from the capital increase of Lavena AD. After this transaction, the share of Sopharma AD in the capital of Lavena AD increased to 5.18%.

Sopharma AD (the “Company”) announces that on 7 February 2014 the Company received a notification for the acquisition of 4 230 000 shares, representing 3.20 % of its capital, by Rompharm Company OOD. After the transaction the share of Rompharm Company OOD in the capital of Sopharma AD reached 17.60%. The registration date of the transaction in the Central Depository AD, Sofia is 2 February 2014.

SOPHARMA AD (the “Company”) hereby informs that from 27 June 2013 up to and including 3 July 2013 the Company bought 14186 own shares representing 0.011% of the share capital of the Company, to the total value of BGN 44612.06 on the Bulgarian Stock Exchange. The average price per share was BGN 3.14.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4420768, representing 3.35% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that for June 2013 the Company realized a decrease of sales revenues of 5 % compared to the same period of 2012, including 21% increase of domestic sales and 13% decrease of export sales.

During the past six months Sopharma AD recorded an increase of sales revenues of 0,01%, including 7% increase of domestic sales and 2% decrease of export sales compared to the same period of 2012.

Sopharma AD (the “Company”) announces that on 6 February 2014 the Company sold 616 015 ordinary registered shares with voting rights of the capital of Sopharma Trading AD. After this transaction, the share of Sopharma AD in the capital of Sopharma Trading AD decreased to 73.99%.

SOPHARMA AD (the “Company”) hereby informs that from 4 July 2013 up to and including 10 July 2013 the Company bought 24738 own shares representing 0.019% of the share capital of the Company, to the total value of BGN 76697.36 on the Bulgarian Stock Exchange. The average price per share was BGN 3.10.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4445506, representing 3.37% of the share capital of the Company.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that Sopharma AD will commence the paying of dividends for 2012 on 29 July 2013 in accordance with a List of Entitled Persons as at 5 July 2013, prepared by the Central Depository.